Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Appoints Emmanuel Ligner as General Manager

Published: Friday, April 11, 2014
Last Updated: Friday, April 11, 2014
Bookmark and Share
Emmanuel will oversee all worldwide commercial activities of Company's rapidly growing BioProcess business.

GE Healthcare Life Sciences has announced the appointment of Emmanuel Ligner as General Manager, Global Commercial for BioProcess.

In this newly-created role Emmanuel will oversee all worldwide commercial activities of GE Healthcare Life Sciences' rapidly growing BioProcess business, which provides innovative “start-to-finish” technologies and services for the biopharmaceutical and vaccine manufacturing industry. Emmanuel reports to Nigel Darby, Vice President, BioProcess.

In March 2014 GE Healthcare Life Sciences expanded its offerings for the biopharmaceutical manufacturing industry through the acquisition of HyClone™ cell culture sera and media.

This investment and other innovations such as KUBio™ modular facility for the production of monoclonal antibodies are core to GE Healthcare’s strategy of helping the biopharmaceutical industry improve product yields and reduce time-to-market.

Before moving into this global role, Emmanuel was General Manager Commercial EMEA in January 2012, joining GE Healthcare in 2008 when the company acquired Whatman plc, a global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Prior to Whatman, Emmanuel held a number of appointments in Japan with Abbott Diagnostics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences Strengthens Business Resilience with ISO 22301
$100 million investment to double manufacturing capacity for chromatography media by 2018.
Saturday, December 05, 2015
GE Healthcare Life Sciences and Emerson Team Up
Collaboration will help drive improvements in productivity.
Saturday, November 28, 2015
GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey
Supports Turkey’s ambitions to expand domestic biopharmaceutical industry. Laboratory will be a key component of GE’s new Innovation Center in Istanbul.
Friday, November 14, 2014
GE Healthcare Life Sciences Named as Finalist for Four Bioprocess Industry Awards
Awards celebrate and recognize the outstanding people, organizations and technologies.
Saturday, October 04, 2014
GE Healthcare Life Sciences to Create New US Headquarters
When fully operational, the new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts.
Wednesday, August 20, 2014
GE Healthcare to Build KUBio Factory for JHL Biotech in China
New factory to give JHL Biotech commercial biopharmaceutical manufacturing capabilities in Asia.
Thursday, September 26, 2013
GE Healthcare Life Sciences and Osaka University Team Up
Top four graduate students to be hosted at GE Healthcare Life Science’s Uppsala site.
Wednesday, August 21, 2013
GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!